Genedrive Plc (LON:GDR) is the topic of conversation when Hardman & Co, life sciences Analyst Dr Dorothea Hill talks to DirectorTalk. Dorothea explains the significance of the recent fundraise, how the proceeds with be used, what stage the technology is currently at, why she considers the commercial potential of Genedrive technology so great and thoughts on the current company valuation.
Genedrive plc is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis of infectious diseases. Rapid analysis of patient samples greatly aids clinical and public health decision-making, with field testing particularly important in emerging markets. The 2018 fiscal year saw solid operational progress to generate first commercial sales. CE marking of the assay for hepatitis C virus (HCV) detection was awarded, and three commercial partnerships were agreed.